

|
| Polycystic ovary syndrome | ||
|---|---|---|
| ICD-10 code: | E28.2 | |
| ICD-9 code: | 256.4 | |
Polycystic ovary syndrome (PCOS, also known clinically as Stein-Leventhal syndrome), is an endocrine disorder that affects 5–10% of women. It occurs amongst all races and nationalities, is the most common hormonal disorder among women of reproductive age, and is a leading cause of infertility. The symptoms and severity of the syndrome vary greatly between women. While the causes are unknown, insulin resistance (often secondary to obesity) is heavily correlated with PCOS.
Contents |
Other names for this disorder include:
There are two definitions that are commonly used:
The Rotterdam definition is wider, including many more patients, notably patients without androgen excess, while in the NIH/NICHD definiton androgen excess is a prerequisite. Critics maintain that findings obtained from the study of patients with androgen excess cannot be necessarily extrapolated to patients without androgen excess.
Common symptoms of PCOS include:
Signs are:
Women with PCOS are at risk for the following:
Some data suggest that women with PCOS have an increased risk of miscarriages. As well, many women with PCOS have a difficult time conceiving, due to the irregular cycles and lack of ovulation. However, it is possible for these women to have normal pregnancies with the aid of medication and diet.
It is vital to note that not all women with PCOS have polycystic ovaries, nor do all women with ovarian cysts have PCOS; although a pelvic ultrasound is a major diagnostic tool, it is not the only one. Diagnosis can be difficult, particularly because of the wide range of symptoms, and the variability of how they present themselves in individuals (which is why this disorder is characterized as a syndrome rather than a disease). There is a lot of controversy about the appropriate testing:
The role of other tests is more controversial, including:
As well, other causes of irregular/absent menstruation and hirsutism such as congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia and other pituitary and/or adrenal disorders, should be investigated.
PCOS develops when the ovaries are stimulated to produce excessive amounts of male hormones (androgens), particularly testosterone - either through the release of excessive luteinizing hormone (LH) by the pituitary gland, or due to high levels of insulin in the blood (hyperinsulinaemia) in women whose ovaries are sensitive to this stimulus.
This syndrome acquired its most widely-used name because a common symptom is multiple (poly) ovarian cysts. These form where egg follicles matured, but were never released from the ovary due to abnormal hormone levels. These generally take on a 'string of pearls' appearance. The condition was first described in 1935 by Dr. Stein and Dr. Leventhal, hence its original name of Stein-Leventhal syndrome.
Although the cause of PCOS is not known, research to date suggests that obesity is a prime indicator. It may have a genetic predisposition and further research into this possibility is currently taking place. No specific gene has been identified, and it is thought that there are many genes that could contribute to the development of PCOS.
A majority of patients with PCOS - some investigators may say all - have insulin resistance. Their increased insulin levels contribute to or cause the abnormalities seen in the hypothalamic-pituitary-ovarian axis that lead to PCOS. Specifically hyperinsulinemia increases GnRH pulse frequency, LH over FSH dominance, increased ovarian androgen production, decreased follicular maturation, and decreased SHBG binding: all these steps leading to the development of PCOS. Insulin resistance is a common finding in obese people.
Medical treatment of PCOS used to be directed mainly at the symptoms (ovarian and adrenal suppression, and anti-androgen therapy) and restoring ovulation. Some medications used for these purposes are:
Recent research suggests that the insulin resistance and over-release of insulin may be at the root of PCOS. Many women find insulin-lowering medications such as metformin hydrochloride (Glucophage®), pioglitazone hydrochloride (Actos®), and rosiglitazone maleate (Avandia®) helpful to them, and indeed ovulation may resume when using these agents. Many women report that metformin use is associated with upset stomach, diarrhea and weight-loss. Both symptoms and weight-loss appear to be less with the extended release versions. Most published studies use either generic metformin or the regular, non- extended release version. Starting with a lower dose and gradually increasing the dosage over 2-3 weeks and taking the medication towards the end of a meal may reduce side effects. The use of basal body temperature charts or BBT charts is an effective way to follow progress. It may take up to six months to see results, but when combined with exercise and a low-glycemic diet up to 85% will improve menstrual cycle regularity and ovulation.
Low-carbohydrate diets and sustained regular exercise are also beneficial. As well, initial research suggests that the risk of miscarriage is significantly reduced when Metformin is taken throughout pregnancy (9% as opposed to as much as 45%); however, further research needs to be done in this area.
For patients who do not respond to these and related medications/procedures, the polycystic ovaries can be treated with surgical procedures such as: